Biocon launches GLP-1 in United Kingdom

28 Feb 2025 Evaluate

Biocon has launched its Glucagon-like peptide-1 (GLP-1) peptide, Liraglutide, for diabetes and obesity, in the United Kingdom (U.K.). The drug-device combination will be marketed in the U.K. under the brand names Liraglutide Biocon for diabetes (gVictoza) and Biolide for chronic weight management (gSaxenda).

The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., earlier this year, making Biocon the first generics company to obtain approval for gLiraglutide in a major regulated market. With GLP-1 therapies projected to be a substantive future growth driver for Biocon, the company remains committed to reinforcing its position as a key player in this area.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.


Biocon Share Price

392.80 4.55 (1.17%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×